Page 69 - CIBERDEM2016-ENG

Most relevant scientific articles
• Mata-Cases M, Franch-Nadal J, Real J, Mauricio D. glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study.BMJ open. 2016;6(10):e012463.
• Alonso N., Lupon J., Barallat J., de Antonio M., Domingo M., Zamora E. et al. Impact of diabetes on the predictive value of heart failure biomarkers. Cardiovascular Diabetology. 2016;15(1).
• Sanahuja J., Alonso N., Díez J., Ortega E., Rubinat E., Traveset A. et al. Increased burden of cerebral small vessel disease in patients with type 2 diabetes and retinopathy. Diabetes Care. 2016;39(9):1614- 1620.
• Akerman I, Tu Z, Beucher A, Rolando DM, Sauty-Colace C, Benazra M et al. Human Pancreatic β Cell lncRNAs Control Cell-Specific Regulatory Networks.Cell metabolism. 2016.
• Mata-Cases M., Casajuana M., Franch-Nadal J., Casellas A., Castell C., Vinagre I. et al. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain. European Journal of Health Economics. 2016.
Highlights
• Beta cell dysfunction and damage
The development of nanotherapy against autoimmunity in type 1 diabetes continues, determining its effects on antigen-specific tolerance and addressing its translational aspect. We are also studying the humoral autoimmune mechanisms involved in the autoimmune diabetes model, i.e. nOD.
We are actively collaborating with other CIBERDEM groups in elucidating the regulatory functions of the non-coding genome in diabetes and in identifying variants involved in the development of type 2 diabetes.
• Complications of diabetes mellitus and associated metabolic conditions
We are working on the identification of markers of subclinical atheromatous disease and lipid metabolism abnormalities in patients with diabetes. The study of markers associated with heart failure in type 2 diabetes has also been initiated in a cohort of patients with heart failure. Competitive funding has been obtained to gain insight in the study of the role of lipotoxicity and microangiopathy in diabetic cardiomyopathy, in both type 1 and type 2 diabetes, in collaboration with another CIBERDEM group and an international group.
A coordinated project with two other CIBERDEM groups on the role of the incretin pathway in obesity and the response to surgical treatment is still being carried out.
• Epidemiology of diabetes: studies with large databases
Studies with databases of real clinical practice (SIDIAP database) are underway concerning aspects of complications, clinical inertia and modeling of the costs of type 2 diabetes being the focus of this research. The group is collaborating in the [email protected] study. The follow-up of this study, in the framework of CIBERDEM on the incidence of diabetes in Spain, has been started. Our group is also leading a pragmatic clinical trial of several primary care centers in Catalonia.
DEM
research groups 69